Jana Pachlopnik Schmid
Jana Pachlopnik Schmid received her MD and PhD degree from the University of Bern, Switzerland. After an internship in General Pediatrics at the University Children’s Hospital, Bern and a clinical training in Pediatric Immunology at the University Children’s Hospital in Zürich, Switzerland, she completed a postdoctoral fellowship in Pediatric Immunology at the Necker Hospital, in Paris under the supervision of Dr. Geneviève de Saint Basile. Her work there was mainly dedicated to preclinical studies on evaluating treatment with neutralizing anti-interferon gamma in hemophagocytic lymphohistiocytosis (HLH), a rare inborn error of immune regulation. This therapeutic strategy became the first FDA approved treatment for HLH. In 2010, she returned to the University Children’s Hospital in Zürich, where she became Assistant Professor of Pediatric Immunology in 2013, Head of the Division of Immunology in 2020 and Professor and Chair of Pediatric Immunology at the University of Zurich in 2021.Dr. Jana Pachlopnik Schmid primary interests include immune regulatory mechanisms and translating the use of targeted treatment from bench to bedside in monogenic immune diseases. She has contributed to the characterization of several novel monogenic immunodeficiencies that include deficiency in CD48, Polymerase ε1, TTC7A, MST1 and, very recently, ZNFX1.